UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)  November 21, 2006

SONUS PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware

 

0-26866

 

95-4343413

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of incorporation)

 

File Number)

 

Identification No)

 

22026 20th Avenue S.E., Bothell, Washington   98021

(Address of principal executive offices)

 

(425) 487-9500

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



Item 1.01     Entry into a Material Definitive Agreement.

On November 21, 2006, Sonus Pharmaceuticals, Inc. (“Sonus”) entered into a lease agreement with BMR-217th Place, LLC to house all of Sonus’ operations at 1522 217th Place SE, Bothell, Washington.  Sonus will be moving from its current location at 22026 20th Ave SE, Bothell, WA.  The lease provides Sonus with approximately 38,000 square feet of office and laboratory space. The lease will commence on September 1, 2007 if certain improvements to the building are substantially completed. The term of the lease is ten years.

2



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

SONUS PHARMACEUTICALS, INC.

 

 

 

 

 

 

Date: November 28, 2006

 

By:

/s/ Alan Fuhrman

 

 

 

 

Alan Fuhrman

 

 

 

Senior Vice President and Chief Financial Officer

 

3